Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10385763 | 0.98 | KCNH2 (0.47) | KCNH2ALDH1A1MIFCYP19A1KDM4E | |
| SCHEMBL27948903 | 0.98 | KCNH2 (0.47) | KCNH2ALDH1A1MIFCYP19A1KDM4E | |
| SCHEMBL27948896 | 0.98 | KCNH2 (0.47) | KCNH2ALDH1A1MIFCYP19A1KDM4E | |
| SCHEMBL27918673 | 0.94 | — | — | |
| Thiophene SCHEMBL28293930 | 0.89 | KCNH2 (0.41) | KCNH2ALDH1A1MIFCYP19A1MGLL | |
| SCHEMBL4722131 | 0.77 | — | — | |
| SCHEMBL28136421 | 0.72 | KDM4E (0.46) | ALDH1A1KDM4EMGLLL3MBTL1 | |
| SCHEMBL20969046 | 0.71 | NOS3 (0.38) | — | |
| SCHEMBL27863173 | 0.71 | HTR2A (0.42) | KCNH2RAB9A | |
| SCHEMBL16804378 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6632775-B1 | Synergistic combination including a 3-aryl-1,3,4-thiadiazol-2(3H)-one; nonphytotoxic to agricultural crops | ISAGRO RICERCA S.R.L. (IT) | 2003-10-14 | — | — | US | claimed |
| US-5948916-A | Arylthiadiazole derivative and antiviral agent containing the same | RATIONAL DRUG DESIGN LABORATORIES (JP) | 1999-09-07 | — | — | US | claimed |
| EP-0785193-A1 | ARYLTHIADIAZOLE DERIVATIVE AND ANTIVIRAL AGENT CONTAINING THE SAME | Rational Drug Design Laboratories (JP) | 1997-07-23 | — | — | EP | claimed |
| CN-109715696-B | Fused thiophene-arylthiadiazole polymers, methods of making the same, and uses thereof | 康宁股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-10759898-B2 | Fused thiophene-arylthiadiazole polymers, methods of making such polymers, and uses thereof | CORNING INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20180079858-A1 | FUSED THIOPHENE-ARYLTHIADIAZOLE POLYMERS, METHODS OF MAKING SUCH POLYMERS, AND USES THEREOF | CORNING INCORPORATED | 2018-03-22 | — | — | US | disclosed |
| WO-2018053226-A1 | FUSED THIOPHENE-ARYLTHIADIAZOLE POLYMERS, METHODS OF MAKING SUCH POLYMERS, AND USES THEREOF | CORNING INCORPORATED (US) | 2018-03-22 | — | — | WO | disclosed |
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | disclosed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2014-05-08 | — | — | US | disclosed |
| EP-2726470-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | reMynd NV (BE) | 2014-05-07 | — | — | EP | disclosed |
| US-5948916-A | Arylthiadiazole derivative and antiviral agent containing the same | RATIONAL DRUG DESIGN LABORATORIES (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0785193-A1 | ARYLTHIADIAZOLE DERIVATIVE AND ANTIVIRAL AGENT CONTAINING THE SAME | Rational Drug Design Laboratories (JP) | 1997-07-23 | — | — | EP | disclosed |
| EP-0785193-A1 | ARYLTHIADIAZOLE DERIVATIVE AND ANTIVIRAL AGENT CONTAINING THE SAME | Rational Drug Design Laboratories (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996009296-A1 | ARYLTHIADIAZOLE DERIVATIVE AND ANTIVIRAL AGENT CONTAINING THE SAME | RATIONAL DRUG DESIGN LABORATORIES (JP) | 1996-03-28 | — | — | WO | disclosed |
| US-5434164-A | Carbostyril derivatives and salts thereof and pharmaceutical compositions for inhibiting adhesion of thrombocytes | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1995-07-18 | — | — | US | disclosed |
| EP-0240015-B1 | Carbostyril derivatives, process for preparing them, pharmaceutical composition, and use | OTSUKA PHARMA CO LTD (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-5008274-A | Carbostyril derivatives and salts thereof and pharmaceutical composition for inhibiting adhesion of thrombocytes | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0240015-A2 | Carbostyril derivatives, process for preparing them, pharmaceutical composition, and use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-07 | — | — | EP | disclosed |
| US-4330552-A | Antiinflammatory 4,5-diaryl-2-arylthioimidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | MAPT, PSEN1, PSEN2 | KCNH2 2629/4885ALDH1A1 1098/4885MIF 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.